Nec Oncoimmunity AS

Research activity includes solid tumors treated alongside anti-PD-1 and anti-PD-L1 therapy, with an emphasis on integrating immune-based approaches into cancer care.

• PD-1 and PD-L1 blockade
• Immune checkpoint therapy
• Solid tumor immunotherapy

The sponsor’s clinical interest is centered on immune-directed treatment strategies for cancers where tumor immune evasion is a major therapeutic challenge.